← Eichor
Study identifier: NCT00078078 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical and Laboratory Study of Methylmalonic Acidemia

Condition: Organic Acidemia · Methylmalonic Acidemia · Inborn Errors of Metabolism  ·  Sponsor: National Human Genome Research Institute (NHGRI)

PhaseN/A
Planned participants2275
Who can joinAll sexes, 1 Month to 115 Years
Healthy volunteersYes

About this study

Methylmalonic acidemia (MMA), one of the most common inborn errors of organic acid metabolism, is heterogeneous in etiology and clinical manifestations. Affected patients with cblA, cblB and mut classes of MMA are medically fragile and can suffer from complications such as metabolic stroke or infarction of the basal ganglia, pancreatitis, end stage renal failure, growth impairment, osteoporosis, and developmental delay. The frequency of these complications and their precipitants remain undefined. Furthermore, current treatment protocol outcomes have continued to demonstrate substantial morbidity and mortality in the patient population. Increasingly, solid organ transplantation (liver, and/or kidney) has been used to treat patients. Disordered transport and intracellular metabolism of vitamin B12 produces a distinct group of disorders that feature methylmalonic acidemia as well as (hyper)homocysteinemia. These conditions are named after the corresponding cellular complementation class - (cblC, cblD, cblF, cblJ and cblX) - and are also heterogenous, clinically and biochemically. The genetic disorders underlying cblE and cblG feature an isolated impairment of the activity of methionine synthase, a critical enzyme involved in the conversion of homocysteine to methionine and these disorders feature (hyper)homocysteinemia. Lastly, a group of patients can have increased methylmalonic acid and/or homocysteine in the blood or urine caused by variant(s) in recently identified (ACSF3) a…

This description comes directly from the study's public registry record.

Talk to the study team

Jennifer L Sloan, Ph.D.  ·  (301) 443-9055  ·  jsloan@mail.nih.gov

Charles P Venditti, M.D.  ·  (301) 496-6213  ·  venditti@mail.nih.gov

Always discuss trial participation with your own doctor first.

Locations (3)

Children's National Medical CenterWashington D.C., District of Columbia, United StatesCompleted
National Institutes of Health Clinical CenterBethesda, Maryland, United StatesRecruiting
UPMC Children's Hospital of PittsburghPittsburgh, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT00078078